Slide 1: Exchange filing cover letter: Investor Presentation
10th May, 2024 (1) BSE Ltd. (2) National Stock Exchange of India Ltd. Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai 400 001 Bandra Kurla Complex Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA
Slide 2: Investor Presentation Q4FY24
Investor Presentation Q4FY24 10-05-2024 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual
Slide 4: Strong Rigor across Geographies; Financial Metrics Continue to Improve
Strong Rigor across Geographies; Financial Metrics Continue to Improve1 Revenue EBITDA PAT 10% 13% 79% Q4FY24 INR 6,163 Cr (YoY) INR 1,316 Cr 54 bps INR 939 Cr 587 bps (YoY) (YoY) 26% 47% FY24 INR 25,455 Cr 14% INR 6,233 Cr 232 bps INR 4,106 Cr 365 bps (YoY) (YoY) (YoY) Business Performance Snapshot
Slide 5: Financial Performance: FY24
Financial Performance2 : FY24 Revenues INR 25,455 Cr EBITDA INR 6,233 Cr Revenue1 Break-up FY24 (Consolidated) API, 2% Others, 1% FY 24 (INR Cr) vs FY23 Emerging Markets & Europe, 12% Total Revenue from 25,455 14.0% Operations EBITDA 6,233 25.9% SAGA, 12% One India, 43% EBITDA % 24.5% 232 bps PAT 4,
Slide 6: Financial Performance: Q4FY24
Financial Performance2 : Q4FY24 Revenues INR 6,163 Cr EBITDA INR 1,316 Cr Revenue1 Break-up Q4FY24 (Consolidated) API, 3% Actuals vs Q4FY23 Others, 2% (INR Cr) Emerging Total Revenue from 6,163 10.0% markets and Operations Europe, 14% One India, EBITDA 1,316 12.9% 39% EBITDA % 21.4% 54 bps SAGA, 12%
Slide 7: FY24 Growth Pillars
FY24 Growth Pillars Market leading growth Big brands bigger Investing in future Regulatory resolutions Organic USFDA • India : Chronic market1 • India: 21 brands in IPM1 top share growth – 10%+ (4-year • North America : Total R&D 300; 22 brands with revenue • VAI received for Invagen CAGR) expenses4
Slide 8: Growth-Oriented Portfolio Recalibration
Growth-Oriented Portfolio Recalibration • OTC brands acquisition of Ivia Beaute • Enhanced OTC Portfolio in South Africa including Astaberry®. Foray into • Distribution and promotion of CNS Investments cosmetics and personal care. • Focused therapies - Women’s health, product range in India Anti-inf
Slide 9: Consistent Growth Focus
Consistent Growth Focus1 INR Cr Revenue EBITDA 7,000 24.5% 30.0% 30,000 25,455 6,000 22.5% 21.0% 22.2% 25.0% 25,000 21,763 22,334 18.9% 5,000 6,233 19,160 4,952 20.0% 20,000 17,132 4,000 4,578 4,303 15.0% 15,000 3,000 3,230 10.0% 10,000 2,000 5,000 1,000 5.0% - - 0.0% FY20 FY21 FY22 FY23 FY24 FY20 F
Slide 10: Strong Net-Cash: Building a War-chest for Growth Investments
Strong Net-Cash : Building a War-chest for Growth Investments INR Cr Total Debt Total Cash1 3,089 8,267 6,273 2,014 4,965 2,816 3,756 1,756 1,056 803 2,009 559 824 520 247 273 259 232 283 312 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 Lease Liabilties Other debt 1. Includes cash and cash equi
Slide 11: One India: Consistent, strong performance across key therapies & segments
One India1 : Consistent, strong performance across key therapies & segments One India Business FY24 Revenue INR 10,865 Cr Q4 Revenue INR 2,417 Cr 3-year CAGR5 16% 3-year CAGR5 13% Branded Prescription Branded Prescription Branded Prescription Branded Prescription Trade Trade Generics Generics Consum
Slide 12: India Branded Prescriptions: Big Brands Bigger
India Branded Prescriptions : Big Brands Bigger Specialty in-licensing business2 INR Cr 761 Brands in top 300 39% 21 CAGR2 FY20-24 brands in IPM1 539 375 264 203 22 Brands with revenue > INR 100 Cr1 FY20 FY21 FY22 FY23 FY24 1st Foracort becomes #1 brand in IPM1 INR 850+ Cr Duolin® Budecort® Dytor® U
Slide 13: India Trade Generics: Establishing Deeper Connect with Strong Growth Levers
India Trade Generics : Establishing Deeper Connect with Strong Growth Levers #1 5,500+ 15,000+ Stockiest Network India’s largest trade Pin codes serviced 150,000+ across India generic business Chemist coverage Big brands bigger 2 Brands with revenue 5 Brands with revenue INR 50 Cr-100 Cr > INR 100 C
Slide 14: FY24: Global Consumer Wellness Franchise Creating Strong Brands
FY24: Global Consumer Wellness Franchise Creating Strong Brands One India : Revenue INR 1,291 Cr Pain relief Nicotine Replacement Hydration Skin infection Cold & cough INR 230+ Cr INR 160+ Cr INR 150+ Cr INR 105+ Cr INR 100+ Cr South Africa : Revenue ZAR 1,476 Mn Respi OTC Cough, cold & flu Cough, c
Slide 15: North America: Key Assets Propelling Robust YoY Growth
North America : Key Assets Propelling Robust YoY Growth $ Mn 3-year CAGR 24% +18% 906 24% 733 8% 594 551 222 229 230 226 195 204 160 179 139 140 137 141 142 150 155 134 14
Slide 16: Focus on driving North America Business through Complex Asset Pipeline
Focus on driving North America Business through Complex Asset Pipeline CLICK TO EDIT MASTER TITLE STYLE Pipeline progress Respiratory • 5 assets filed (launches expected in 1-3 years for major assets) Pipeline • 2 assets to be filed over next 12-15 months Peptides & • 12 assets filed (most launches
Slide 17: ANDA & NDA Portfolio & Pipeline (As on 31st March 2024)
ANDA & NDA Portfolio & Pipeline (As on 31st March 2024) 14 61 9 3 18 8 80 2 2 52 20 8 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 164 32 81 277 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDA
Slide 18: SAGA: Steady Growth across Businesses
SAGA1: Steady Growth across Businesses $ Mn Q4 $ Mn FY24 52 76 9 9 16 64 52 19 56 68 226 241 Q4FY23 Q4FY24 FY23 FY24 SA Private SA Tender Others (SSA & CGA) SA Private SA Tender Others (SSA & CGA) Market Segment2 Rank Share Cipla Growth Market Growth SA Key Highlights2 South Africa Prescription 1 8.
Slide 19: Emerging Markets & Europe and API
Emerging Markets & Europe and API $ Mn Emerging Markets & Europe API Revenue Revenue 100 23 95 16 Q4FY23 Q4FY24 Q4FY23 Q4FY24 Revenue Revenue 376 373 71 70 FY23 FY24 FY23 FY24 18
Slide 20: ESG Update
ESG Update Progress on ESG 32.7 % RE2 44 % waste compared to landfill to 9% in Completed Scope 3 emissions baselining for FY23 FY20 Solar Rooftop with annual capacity of 1.2 mn units, installed in Kundaim in Dec-23 & 0.7 mn 61 % units in Satara in Mar-24 27.2 % Waste GHG1 disposal Watershed program
Slide 21: Profit and Loss Statement Summary (Reported)
Profit and Loss Statement Summary (Reported)1 INR Cr Particulars Q4 FY24 FY24 Revenue from sale of products 6,082 25,447 Other operating income 81 328 Income from operations 6,163 25,774 Material cost 2,050 8,820 Employee benefits expense 1,084 4,310 Other expenses 1,713 6,353 Total expenses 4,847 1
Slide 22: Balance Sheet summary (Reported)
Balance Sheet summary (Reported) INR Cr Particulars Mar-24 Mar-231 Net Tangible Assets 6,047 5,740 Goodwill & Intangibles 4,713 4,514 Investments 642 573 Other non-current assets 406 352 Advance tax assets (net) 442 531 Deferred tax assets (net) 403 293 Inventories 5,238 5,156 Cash and Cash Equivale
Slide 23: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Ajinkya Pandharkar Investor.Relations@cipla.com Diksha Maheshwari Investor.Relations@cipla.com For more information, please visit www.c